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RADIATION ONCOLOGY PHYSICS
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Abstract
Purpose/objectives: Due to higher radiosensitivity, non‐target normal tissue dose is
a major concern in stereotactic body radiation therapy (SBRT) treatment. The aim of
this report was to estimate the dosimetric impact, speciﬁcally the reduction of
normal lung dose in the treatment of single‐isocenter/two‐lesion lung SBRT via
volumetric modulated arc therapy with jaw tracking (JT‐VMAT).
Materials/methods: Twelve patients with two peripherally located early‐stage
non‐small‐cell‐lung cancer (NSCLC) lung lesions underwent single‐isocenter highly
conformal non‐coplanar JT‐VMAT SBRT treatment in our institution. The mean
isocenter to tumors distance was 5.6 ± 1.9 (range 4.3–9.5) cm. The mean combined
planning target volume (PTV) was 38.7 ± 22.7 (range 5.0–80.9) cc. A single isocenter
was placed between the two lesions. Doses were 54 and 50 Gy in three and ﬁve
fractions, respectively. Plans were optimized in Eclipse with AcurosXB algorithm
utilizing jaw tracking options for the Truebeam with a 6 MV‐FFF beam and standard
120 leaf millennium multi‐leaf collimators. For comparison, the JT‐VMAT plans were
retrospectively re‐computed utilizing identical beam geometry, objectives, and planning parameters, but without jaw tracking (no JT‐VMAT). Both plans were normalized to receive the same target coverage. The conformity and heterogeneity indices,
intermediate‐dose spillage [D2cm, R50, Gradient Index (GI), Gradient Distance (GD)],
organs at risks (OAR) doses including normal lung as well as modulation factor (MF)
were compared for both plans.
Results: For similar target coverage, GI, R50, GD, as well as the normal lung V5, V10,
V20, mean lung dose (MLD), and maximum dose received by 1000 cc of lungs were
statistically signiﬁcant. Normal lung doses were reduced by 8%–11% with JT‐VMAT.
Normal lung dose increased as a function of tumor distance from isocenter. For the
other OAR, up to 1%–16% reduction of non‐target doses were observed with JT‐
VMAT. The MF and beam‐on time were similar for both plans, however, MF increased
as a function of tumors distance, consequently, delivering higher dose to normal lungs.
Conclusion: Utilizing jaw tracking options during optimization for single‐isocenter/
two‐lesion lung SBRT VMAT plans reduced doses to the normal lung and other
OAR, reduced intermediate‐dose spillage and provided superior/similar target coverage. Application of jaw tracking did not affect delivery efﬁciency and provided
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excellent plan quality with similar MF and beam‐on time. Jaw tracking is recommended for future clinical SBRT plan optimization.
PACS
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1 | INTRODUCTION

project were to quantify the dosimetric differences of JT technique
for FFF beam in the SBRT treatment of multifocal lung lesions

Recent advances in stereotactic body radiotherapy (SBRT) technol-

and to investigate the JT delivery complexity with MLC movements.

ogy have greatly improved the ability to deliver conformal therapeu-

In this report we retrospectively evaluated 12 single‐isocenter/two‐

tic tumor dose with a biological effective dose (BED) of greater than

lesion early stage NSCLC patient's plans who underwent SBRT

100 Gy while minimizing the dose to the adjacent organs at risk

treatment in our clinic using JT‐VMAT. For those patients, the non‐

(OAR).1–3 Several studies have shown that safely delivering a higher

target low dose was minimized by using jaw tracking options for the

BED to the lung lesions improved therapeutic ratio and local control

Truebeam Linac with a 6 MV‐FFF beam (in Eclipse treatment

rates.4–10 In addition, utilizing volumetric modulated arc therapy

planning system (TPS), Varian Medical System, Palo Alto, CA) during

(VMAT) planning with a ﬂattening ﬁlter free (FFF) beam in lung

SBRT VMAT plan optimization. For comparison, the clinical JT‐VMAT

SBRT treatment reduced the total number of monitor units

plans were re‐computed without jaw tracking (no‐JT‐VMAT) options.

(MUs)11,12 and the treatment time compared to intensity modulated

The original clinical JT‐VMAT and no‐JT‐VMAT plans were compared

radiotherapy, Tomotherapy, or CyberKnife.13–16 Reduction in MUs

via lung SBRT protocol compliance criteria, target conformity,

provides faster treatment delivery that can improve patient comfort,

gradient indices, dose to lungs, and other OAR per RTOG guidelines.

decrease potential setup/motion related errors and promote efﬁcient
clinical workﬂow. Owing to those advantages, VMAT SBRT planning
using single isocenter for multiple targets has been gaining popularity
in clinics for treating multiple intracranial tumors17,18 as well as
extracranial oligometastases lesions.19–23
Conversely, VMAT averages the dose delivery over more angles

2 | MATERIALS AND METHODS
2.A | Computed tomography (CT) simulation and
contouring

and produces slightly higher non‐target low dose distribution com-

A total of 12 sequential patients who underwent single‐isocenter/

pared to intensity modulated radiation therapy (IMRT). Generally, the

two‐lesion lung SBRT treatment in our clinic were included in this

treatment ﬁelds are designed with the jaw apparatus and tertiary

retrospective study, all of whom had two peripherally located Stage I

multi‐leaf collimators (MLCs) shaping the target volume. The jaw

NSCLC lesions. The patients were immobilized using Body Pro‐Lok™

apparatus is ﬁxed on the maximum ﬁeld size of MLCs during treat-

platform (CIVCO system, Orange City, IA) in the supine position,

ment delivery, and thus leakage and transmission of radiation

arms above their head with abdominal compression. All patients

through the MLCs is present in the optimized IMRT/VMAT plan. This

received four‐dimensional (4D)‐CT scan using Varian's Real Time

effect is noticeable while utilizing single‐isocenter/multitarget VMAT

Position Management Respiratory Gating System (version 1.7) in

plan. When the isocenter to tumor distance is large (on the order of

addition to conventional three‐dimensional (3D) CT scan on a GE

4–10 cm), the MLCs have to travel a longer distance to provide the

Lightspeed 16 slice CT scanner (General Electric Medical Systems,

target coverage to each lesion, potentially delivering higher non‐tri-

Waukesha, WI). CT images were acquired with 512 × 512 pixels at

vial low‐dose spillage to the non‐target tissues such as normal lungs.

2.5 mm slice thickness in the axial cine mode. All 10 phases of 4D

Due to the higher radiosensitivity, non‐target normal tissue dose is

CT slices and respiratory motion signal were transferred to an

one of the major concerns for SBRT treatments.24–27 However, if

Advantage 4D Workstation (General Electric Medical Systems, San

the jaws move to track MLC positions (called jaw tracking, JT tech-

Francisco, CA), where the maximum intensity projection (MIP)

nique on Truebeam), the radiation transmitted, and leakage dose to

images were generated after phase binning of the 4D CT images. In

the normal tissues can be reduced.

addition to the MIP images, a physicist conﬁrmed the motion of both

Although the advantages of JT‐IMRT/VMAT plans with ﬂattened
28–32

tumors was less than 1 cm. The regular 3D CT scan and the MIP

the dosimetric impact of

images were imported into the Eclipse TPS (version 13.0, Varian

JT technique with FFF beam in the treatment of lung SBRT patients,

Medical Systems, Palo Alto, CA) and co‐registered for target

along with the treatment delivery complexity due to the use of JT

contouring. Gross tumor volumes (GTV) and internal tumor volumes

with MLC motion has not yet been reported. The goals of this

(ITV) were delineated on the 3D CT images with reference to the

beams have been studied previously,
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MIP images. Planning target volumes (PTV) were generated by add-

medium was reported. All clinical plans were inversely optimized

ing non‐uniform 5–10 mm margins to the ITV to accommodate the

using variation of gantry rotation speed, dose rate, and MLC

patient setup uncertainties based on tumor size, location, and syn-

positions. In addition to optimization ring structures, the generalized

chronous tumor motion. The critical structures, such as bilateral

normal tissue objective (NTO) parameters were used to control the

lungs excluding the ITV (normal lung), spinal cord, ribs, heart, great

gradients for each target. Planning objectives were per RTOG 0915

vessels, esophagus, and skin were delineated on the 3D CT images.

guidelines. These patients were treated every other day per lung

The tumor characteristics for the single‐isocenter/two‐lesion lung

SBRT protocol.

SBRT patients are summarized in Table 1, including isocenter to
tumors distance, normal lung volume, and tumor location. The
combined PTV was deﬁned as PTV1 plus PTV2. Both lesions were

2.B.2 | Quality assurance and treatment delivery

treated synchronously with a total dose of 54 Gy or 50 Gy in three

For each plan, a veriﬁcation plan was generated in the Eclipse TPS

and ﬁve fractions, respectively. Normal lung volume ranged from

using an Octavius phantom (PTW, Freiburg, Germany). Doses re‐cal-

1893 to 6543 cc, mean 3881 cc. The average value of isocenter to

culated on the phantom's 2D ionization chamber array were

tumors distance was 5.6 cm (range 3.4 to 9.5 cm).

exported and compared to a measured dose distribution. Using the
γ‐evaluation method of VeriSoft (Version 6.3, PTW) the two distribu-

2.B | Treatment planning
2.B.1 | Clinical single‐isocenter JT‐VMAT plan

tions were compared using the standard clinical gamma passing rate
criteria of 3%/3 mm maximum dose difference and distance‐to‐
agreement with 10% threshold as well as maximum point dose. The

Highly conformal, clinically optimal VMAT treatment plans were

Octavius QA pass rates for the single‐isocenter/two‐lesion lung SBRT

generated using 3–5 non‐coplanar partial arcs (5–10°, couch kicks

plan were 98.8 ± 2.5%, on average, for 3%/3 mm clinical gamma

were used for arcs) for the Truebeam linear accelerator (Varian, Palo

pass rate criteria and the maximum point dose measurement was

Alto, CA) with millennium MLC and a 6 MV‐FFF (1400MU/min)

1.0 ± 0.7%, on average, suggesting that lung SBRT plans using JT

beam. A single isocenter was placed approximately between the two

can be accurately delivered. The beam‐on time was estimated by

lesions in each patient. For each arc, collimator angles were chosen

using dose rates of 1400 MU/min for these plans. The dose‐rate was

such that the opening of the MLC between tumors was minimized.

conﬁrmed by reviewing each VMAT arc for all patients under the

Additionally, the jaw tracking (JT) option was chosen during plan

MLC properties in Eclipse. Additionally, maximum dose rate of

optimization to further minimize the non‐target dose. A dose of 54

1400 MU/min was visually observed during VMAT QA delivery at

or 50 Gy in three and ﬁve fractions was prescribed to the PTV of

Truebeam for all single‐isocenter/two‐lesion lung SBRT plans.

which D95% received at least 100% of the prescription. All hot

Before delivering each JT‐VMAT SBRT treatment, a daily quality

spots were within each ITV (i.e., the center of each ITV was 20%

assurance check on kilovoltage to megavoltage imaging isocenter

hotter). All clinical treatment plans were calculated using the Eclipse

coincidence was performed, including IsoCalc measurement for

TPS with Acuros XB (version 13.6.0, Varian Medical Systems, Palo

precise and accurate target localization. Our IsoCalc localization

Alto, CA) algorithm on the 3D CT images with heterogeneity correc-

accuracy for Truebeam was <0.5 mm. All the quality assurance

tions using a 2.0 × 2.0 × 2.0 mm3 dose calculation grid‐size. Dose to

procedures were in compliance for SBRT treatment delivery.

T A B L E 1 Characteristics of single‐isocenter/two‐lesion lung
stereotactic body radiation therapy (SBRT) patients treated with
volumetric modulated arc therapy with jaw tracking (JT‐VMAT) plan
included in this study.

procedures established in our clinic.

The patients received daily cone beam CT per image‐guidance

2.B.3 | No JT‐VMAT plan

Mean ± SD
(range or no. of patients)

The JT‐VMAT SBRT treatment plans for all patients were retrospec-

Parameters
Lesion 1, PTV1 (cc)

21.5 ± 20.7 (5.0–80.9)

objectives used in the no JT‐VMAT were identical to the JT‐VMAT

Lesion 2, PTV2 (cc)

17.2 ± 10.7 (7.7–43.6)

plan including the NTO parameters and ring structures. The no

Combined PTV (cc)

38.7 ± 22.7 (15.9–91.8)

JT‐VMAT SBRT plan received the same target coverage as the

Prescription dose (each lesion)

54 Gy in three fractions (six patients)

JT‐VMAT plan. Dosimetric parameters for the target coverage

50 Gy in ﬁve fractions (six patients)

and the dose to adjacent OAR including normal lung doses were

Normal lung volume (cc)

3881 ± 1161 (1893–6543)

Isocenter to tumors distance
(cm)

5.6 ± 1.9 (3.4–9.5)

Tumor location

Left lung lesions (four patients)

tively computed with a no JT‐VMAT approach. All the planning

evaluated.

2.C | Plan evaluation
Right lung lesions (two patients)
Bilateral lungs lesions (six patients)

The dose volume histograms (DVHs) and isodose curves of JT‐VMAT
vs no JT‐VMAT plans were compared. The Conformity index (CI),
heterogeneity index (HI), gradient index (GI), gradient distance (GD),

58

|

and D2cm were calculated per RTOG 0915 recommendations. The
dose to the normal lung was evaluated using V5, V10, V20, mean
lung dose (MLD), and maximum dose to 1000 cc of lungs. Furthermore, dosimetric disparities were evaluated for spinal cord, heart,
bronchial tree, esophagus, trachea, ribs, and skin following RTOG
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T A B L E 2 Plan quality evaluation for single‐isocenter/two‐lesion lung
stereotactic body radiation therapy (SBRT) volumetric modulated arc
therapy with jaw tracking (JT‐VMAT; clinical) and no JT‐VMAT (re‐
planned) plans for all 12 patients.
Target
volume

No
JT‐VMAT

P‐value

Parameters

JT‐VMAT

CI

1.04 ± 0.02

1.05 ± 0.03

n.s.

HI

1.17 ± 0.02

1.17 ± 0.03

n.s.

R50 (%)

5.30 ± 0.88

5.47 ± 0.92

P = 0.001

from the single isocenter, the isocenter to tumor distance was calcu-

D2cm (%)

55.18 ± 6.30

55.43 ± 5.94

lated as the maximum 3D‐linear distance from the isocenter to the

GI

5.12 ± 0.82

5.26 ± 0.87

P = 0.001

geometric center of each tumor. This distance was calculated in the

GD (cm)

1.46 ± 0.16

1.49 ± 0.18

P = 0.0002

guidelines. The mean and standard deviation values for each of the
dose metrics were compared using paired t tests for JT‐VMAT vs no
JT‐VMAT using P < 0.05.
To estimate the normal lung dose as a function of target distance

Eclipse TPS using the x‐, y‐, and z‐ primary coordinates of the tumor
centers. Moreover, the modulation factor (MF) as a function of
isocenter to tumor distance was evaluated by using total number of
monitor units (MUs) delivered for the both JT‐VMAT and no‐JT
VMAT SBRT plans. The MF is deﬁned as the total number of MUs
divided by the prescription dose in cGy.

3 | RESULTS
3.A | Targets coverage

Combined
PTV

n.s.

Combined planning target volume (PTV) = PTV1 plus PTV2. CI = conformity index, total volume covered by the 100% isodose line divided by
the volume of the combined PTV. HI, heterogeneity index = D10%/
D95%, where D10% is the dose to the hottest 10% of the combined
PTV and D95% is the dose to the 95% of the combined PTV coverage.
R50 (%) = ratio of 50% prescription isodose volume to the combined
PTV. D2 cm (%) = maximum dose (in % of dose prescribed) 2 cm away
from PTV in any direction. GI = R50%/R100%, R50% is the ratio of 50%
prescription isodose volume to the combined PTV and R100% is the
ratio of 100% prescription isodose volume to the combined PTV. GD
(cm) = is the average distance from 100% prescription dose to 50% of
the prescription dose. Statistically signiﬁcant P-values are in bold, n.s.
= not signiﬁcant.

Both plans were normalized to receive the same target coverage
(i.e., PTVD95 = 100%). Although jaw tracking was applied for
JT‐VMAT compared to no JT‐VMAT plan, the dose distribution in

3.B | Dose to lungs

the target volumes remained comparable with no signiﬁcant differ-

The absolute differences between single‐isocenter JT‐VMAT and no

ences in conformity and uniformity indices, as shown in Table 2. An

JT‐VMAT SBRT plans for normal lung V20, V10, V5, MLD, and the

example isodose distribution and DVHs are shown in Figs. 1 and 2,

maximum dose received by 1000 cc of lungs are listed in Table 3.

respectively. Although both plans were acceptable per the RTOG

All patients had V20 < 10%–15% for JT‐VMAT treatment plans per

standard, the JT‐VMAT plan had advantages of providing tighter

protocol. The absolute differences of V20, V10, and V5 were up to

intermediate‐dose spillage (see R50, GI, and GD, signiﬁcant P‐values

2%, 3%, and 4% higher, respectively with no JT‐VMAT plans. Doses

in Table 2) compared to no JT‐VMAT plan.

to all lung parameters increase uniformly with no JT‐VMAT plan

F I G . 1 . Comparison of dose distributions for a patient with two lung lesions treated with single‐isocenter volumetric modulated arc therapy
with jaw tracking (JT‐VMAT) stereotactic body radiation therapy (SBRT) plan (left panel). The single‐isocenter location is shown by the cross‐
hair. This patient received a synchronous SBRT treatment to a total dose of 50 Gy to each lesion in ﬁve fractions. Tumors were located in
bilateral lungs. Isocenter to tumors distance was about 8 cm. Lesion 1, planning target volume (PTV)1 (left lung) = 80 cc and lesion 2, PTV2
(right lung) = 11 cc. For the similar target coverage, conformity, and heterogeneity, the intermediate‐dose spillage (see 40% isodose lines
corresponding to 20 Gy dose on both plans) was tighter (more clinically shaped) with volumetric modulated arc therapy with jaw tracking (JT‐
VMAT; left panel) compared to no JT‐VMAT (right panel).

POKHREL

|

ET AL.

59

F I G . 2 . Dose volume histograms (DVHs) comparison between volumetric modulated arc therapy with jaw tracking (JT‐VMAT) and no JT‐
VMAT plans for an example case shown in Fig. 1. As shown above, this patient received a single‐isocenter/two‐lesion JT‐VMAT plan. Square
markers show DVH for no JT‐VMAT, triangle markers show DVH calculated with JT‐VMAT and demonstrate that combined planning target
volume (PTV; purple color) and combined internal tumor volumes (ITV; red color) had an identical target coverage. Ribs (green color) and spinal
cord (light orange color) DVHs are also shown as well as lungs minus ITVs (light blue color). The clinical JT‐VMAT signiﬁcantly reduced low‐
dose spillage to the normal lungs.
T A B L E 3 Normal lung dose statistics between single‐isocenter/two‐lesion volumetric modulated arc therapy with jaw tracking (JT‐VMAT) and
no JT‐VMAT plans for all 12 lung stereotactic body radiation therapy (SBRT) patients. Mean ± standard deviation (range) and P‐values were
presented.
Plan type

V20 (%)

V10 (%)

V5 (%)

MLD (Gy)

Maximum dose to
1000 cc of lungs (Gy)

JT‐VMAT

6.6 ± 3.5 (2.9 to 13.5)

18.5 ± 8.6 (8.2 to 36.8)

31.3 ± 11.4 (15.4 to 50.4)

5.6 ± 3.5 (3.0 to 9.2)

6.2 ± 3.1 (2.3 to 11.2)

No JT‐VMAT

7.3 ± 3.9 (3.0 to 15.4)

20.3 ± 9.5 (8.4 to 39.1)

33.6 ± 12.4 (16.0 to 53.6)

6.1 ± 2.1 (3.2 to 9.9)

6.9 ± 3.5 (2.6 to 12.9)

No JT‐VMAT minus
JT‐VMAT

0.7 ± 0.6 (0.2 to 1.9)

1.9 ± 1.7 (0.2 to 6.5)

2.3 ± 1.9 (0.6 to 6.5)

0.5 ± 0.4 (0.2 to 1.6)

0.7 ± 0.6 (0.3 to 2.1)

P‐value

P = 0.002

P = 0.003

P = 0.001

P = 0.001

P = 0.001

Statistically signiﬁcant P-values are in bold.

compared to JT‐VMAT plan, giving statistically signiﬁcant differences

explained by the fact that MLC transmission contributed low‐dose

(P = 0.002, 0.003, 0.001, 0.001, and 0.001, respectively). Statistically

spillage in the normal lung due to MLC traveling longer distances (as

signiﬁcant P‐values are in bold (see Table 3).

a function of isocenter to tumor distance) to provide the same target

The variation of ratios between no JT‐VMAT and JT‐VMAT as a

coverage.

function of isocenter to tumor distance for V5, V10, V20, MLD, and
maximum dose to 1000 cc of lungs including absolute differences is
shown in Fig. 3. For identical planning objectives and optimization

3.C | Dose to other OAR

parameters, V5, V10, V20, MLD, and maximum dose to 1000 cc of

A comparison of other OAR dosimetric parameters for single‐isocen-

lungs were uniformly higher by 6% (range, 2%–16%), 8% (range, 2‐

ter/two‐lesion JT‐VMAT and no JT‐VMAT plans for all 12 lung SBRT

29%), 8% (range, 2%–22%), 8% (range, 3%–25%), and 11% (range,

patients is presented in Table 4. Critical organs such as spinal cord

2%–19%), on average, respectively, compared to clinical JT‐VMAT

(Dmax, and D0.35cc), heart (Dmax and D15cc), esophagus (Dmax and

plan. In terms of absolute differences, V20, V10, V5, and MLD were

D5cc), bronchial tree (Dmax), trachea (Dmax and D4cc), ribs (Dmax and

higher by up to 1.9%, 6.5%, 6.5%, and 1.6 Gy (in some cases) with

D1cc), and skin (Dmax and D10cc) were evaluated per SBRT protocol

no JT‐VMAT compared to JT‐VMAT, respectively. This could be

guidelines.
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F I G . 3 . Scatter plot: Ratios of normal
lungs V5, V10, V20, MLD, and maximum
dose to 1000 cc of lungs calculated by
volumetric modulated arc therapy with no
jaw tracking (no JT-VMAT) and JT‐VMAT
plans as a function of isocenter to tumor
distance. For the identical plan parameters
and objectives, the no JT‐VMAT plans
gave higher V5, V10, V20, MLD and
maximum dose to 1000 cc of lungs by 6%,
8%, 8%, 8%, and 11%, on average,
respectively, compared to JT‐VMAT plans.

T A B L E 4 Average values and ranges of absolute dose differences between volumetric modulated arc therapy with no jaw tracking (no JT‐
VMAT) vs JT‐VMAT plans for the major dose distribution parameters of the other OAR for all 12 lung stereotactic body radiation therapy
(SBRT) patients.
Range (Gy)

Ratioa

p‐value

0.2 ± 0.9

−1.7 to 3.4

1.02 ± 0.12

n.s.

D0.35cc

0.2 ± 0.7

−0.6 to 2.1

1.03 ± 0.10

n.s.

Dmax

0.2 ± 1.3

−1.7 to 3.0

1.02 ± 0.08

n.s.

OARs

Parameters

Spinal cord

Dmax

Heart
Esophagus

Bronchial tree

Trachea

Ribs

Skin

Mean ± SD (Gy)

D15cc

0.5 ± 0.6

−0.6 to 1.4

1.04 ± 0.06

P = 0.01

Dmax

‐0.3 ± 2.0

−4.3 to 3.4

1.01 ± 0.14

n.s.

D5cc

0.2 ± 0.6

−0.5 to 1.4

1.02 ± 0.07

n.s.

Dmax

0.7 ± 1.6

−1.7 to 3.4

1.06 ± 0.13

n.s.

Dmax

0.4 ± 1.1

−1.1 to 3.0

1.06 ± 0.12

n.s.

D4cc

0.6 ± 0.8

0.0 to 2.4

1.16 ± 0.12

P = 0.02

Dmax

‐0.2 ± 1.7

−4.1 to 2.0

0.99 ± 0.05

n.s.

D1cc

0.1 ± 0.9

−2.4 to 1.5

1.00 ± 0.03

n.s.

Dmax

0.2 ± 1.6

−3.3 to 2.4

1.01 ± 0.09

n.s.

D10cc

0.3 ± 0.4

−0.6 to 0.9

1.03 ± 0.03

P = 0.01

Absolute dose differences = no JT‐VMAT ‐ JT‐VMAT. The negative sign indicates that the results of the JT‐VMAT plans were larger than those of single‐isocenter plans. Mean ± standard deviation, range, and P‐values were presented. Statistically signiﬁcant P‐values are in bold. OAR: organs at risks.
a
Ratio = no JT‐VMAT/JT‐VMAT and n.s. = not signiﬁcant.

It was observed that the volumetric dose difference to heart,

given lung SBRT plan, the total number of MUs did not change

trachea, and skin were statistically signiﬁcant (P‐values, 0.01, 0.02,

signiﬁcantly while using JT options for plan optimization, suggest-

and 0.01, respectively) between the two plans. Overall, the doses

ing that the both plans gave similar MF. The average values of

with no JT‐VMAT SBRT were higher by 1%–16% for the most of

the MF for no JT‐VMAT vs JT‐VMAT were 3.72 ± 0.97 vs

the critical organs, suggesting that the average values of absolute

3.75 ± 0.94, respectively. The average beam on time for JT‐VMAT

dose differences could be higher with no JT‐VMAT plan of the order

plan was 3.8 ± 1.7 min similar to that of no JT‐VMAT plan

of 1–2 Gy compared to clinical JT‐VMAT plan.

(3.7 ± 1.1 min) thus not affecting the beam‐on time, signiﬁcantly.
However, MF increases as a function of isocenter to tumor

3.D | Modulation factor and beam‐on time

distance (see right panel in Fig. 4), suggesting that farther apart
the tumors, the more MUs are required to deliver the target

The MF for no JT‐VMAT vs JT‐VMAT and the MF as a function

coverage and consequently more low‐dose spillage to the non‐tar-

of the isocenter to tumor distance is shown in Fig. 4. For the

get tissues.
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F I G . 4 . Scatter plots: volumetric modulated arc therapy with no jaw tracking (no JT‐VMAT) modulation factor (MF) as a function of JT‐
VMAT (left panel) and MFs as a function of isocenter to tumor distance (right panel) for all 12 single‐isocenter/two‐lesion lung stereotactic
body radiation therapy patients. The JT‐VMAT did not change the total number of MUs or delivery efﬁciency compared to no JT‐VMAT (see
left panel).

4 | DISCUSSION

mechanical parameters only. The ﬁxed jaw plans were not optimized
using the same objectives for clinical use.

In the present study, we investigated the potential reduction of

While agreeing with aforementioned retrospective reports, our

normal lung dose while utilizing jaw tracking options in the treat-

clinically optimized synchronous JT‐VMAT plan exhibits superior

ment of single‐isocenter/two‐lesion lung SBRT patients. For similar

OAR protection for normal lung doses as well as other OAR sparing

target coverage, our JT‐VMAT plan provided lower dose to lungs,

prospectively compared to no JT‐VMAT for the given complexity of

tighter intermediate‐dose spillage and relatively lower dose to OAR

single‐isocenter/two‐lesion lung SBRT setting. By tracking the jaws

compared to no JT‐VMAT plan (see Tables 2, 3, and 4). Most impor-

during SBRT VMAT plan optimization, the magnitude of normal lung

tantly, the low‐dose spillage to the normal lung (V5, V10, V20, MLD,

dose reductions (the OAR closest to the multiple targets) observed

and maximum dose to 1000 cc of lungs) decreased signiﬁcantly with

in this study were generally consistent with previous studies,28–34

JT‐VMAT, up to 11% on average, compared to no JT‐VMAT. Similar

yet relatively higher differences (up to 11%) were observed, perhaps

MF between the two plans suggests that the total number of the

due to the unique complexity of the clinical situations and the

MUs remained similar, therefore, the treatment delivery efﬁciency

distance between the tumors. It is worthwhile to mention that MLC

was not affected by the use of jaw tracking. However, as the

transmission of our 6 MV‐FFF beam was 1.2% and was modeled by

distance between the two lesions increased the MF increased and,

the TPS and incorporated in the dose calculation.
One of the major concerns for treating multiple lung lesions

in general, the low‐dose spillage to the normal lung increased.
A few investigators have reported the dosimetric advantages of

synchronously using single‐isocenter SBRT plan was the non‐trivial

jaw tracking techniques for IMRT and VMAT planning.28–32 For

low‐dose spillage in the normal lung, such as V20, V10, V5,

32

has shown the overall reduction of normal

and MLD, as described above. Per RTOG recommendation, all of

tissues V5, V10, and V20 doses by about 2% when applying jaw

our single‐isocenter/two‐lesion JT‐VMAT lung SBRT plans had

tracking for the step‐and‐shoot IMRT. Another retrospective study

V20 < 10%–15%. Moreover, for our JT‐VMAT plans normal lung

by Kim et al.31 assessed the potential advantages of jaw tracking

V5 and MLD were kept less than 40% and 6.0 Gy, on average,

technique by using control point sequence of VMAT planning for

respectively.25–27 It was observed that when the isocenter to tumor

head and neck, thoracic, abdominal, and prostate patients. For the

distance increased, the normal lung V20, V10, V5, MLD, and maxi-

head and neck cases, the OAR mean dose was reduced by 4.3% to

mum dose to 1000 cc of normal lung increased. Our treatment

12% with jaw tracking. For all prostate patients, the dose reduction

planning strategy favored minimizing lung dose with the jaw track-

was more signiﬁcant in the dose regions of D80 to D95 compared

ing approach. By selecting patient speciﬁc collimator angles in

instance, Joy et al.

32

has

conjunction with jaw tracking the MLC transmission and leakage

shown that maximum and mean doses to the various OAR for head

dose due to the leaves traveling in between two tumors can be

and neck, thoracic, abdominal, and pelvis patients were reduced by

minimized. This can potentially help reduce severe lung toxicity

up to 7 and 3 Gy, respectively, with artiﬁcially locking the jaw coor-

with careful attention to normal lung dose parameters such as V5,

dinates of the jaw tracking VMAT plan. However, in their study, the

V10, V20, and MLD during VMAT plan optimization and perhaps

VMAT plans were not intended for clinical use, but were created for

JT‐VMAT plan may decrease the probability of developing radia-

the evaluation of jaw tracking technique on the basis of identical

tion‐induced acute or late side effects.

to D5 to D20 with jaw tracking. Another study by Wu et al.
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In summary, the potential beneﬁt of applying jaw tracking

approach in Truebeam (with 6MV‐FFF beam) for single‐isocenter/
multitarget lung SBRT setting with curative therapeutic dose of
BED > 100 Gy has been presented. It is shown that jaw tracking
during SBRT VMAT plan optimization potentially reduces doses to
OAR speciﬁcally signiﬁcantly reducing dose to normal lungs while
providing similar target coverage. The main advantages of jaw tracking method were more applicable for treating dispersed multiple
lesions with relatively higher prescription dose per fraction (longer
treatment time) such as the examples presented here or for irregular
larger target volume near the critical structures. Therefore, to minimize non‐target dose we strongly recommend jaw tracking approach
to be applied during VMAT SBRT plan optimization, thereby reducing the MLC leakage and transmission and potentially minimizing
unwanted dose to the patients.

5 | CONCLUSION
Similar target coverage yet more clinically shaped intermediate dose
fall‐off and OAR sparing have been achieved by utilizing the jaw
tracking options at Truebeam for 6 MV‐FFF beam during VMAT plan
optimization in the treatment of single‐isocenter/two‐lesion lung
SBRT. In this setting, the main advantages of jaw tracking options
were observed in the low‐dose spillage to the normal lungs. Similar
values of MF for JT‐VMAT and no JT‐VMAT suggest that overall
treatment time did not increase signiﬁcantly due to jaw tracking with
perhaps similar plan delivery complexity. However, a higher value of
MF was observed for the tumors located far from each other, and
hence the higher dose to the normal lungs. The reduction of normal
lung and OAR dose by jaw tracking during SBRT procedures can
potentially reduce the risk of acute/late toxicity.
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